Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Biotechnologies Assets S.A. (BST.MC) focuses on developing innovative biopharmaceutical products targeting rare diseases, primarily in Europe and North America. The company leverages its proprietary drug delivery technology, which enhances the efficacy of existing therapies, setting it apart from competitors in the biotechnology space.
BST.MC generates revenue primarily through the sale of its proprietary biopharmaceutical products, which are designed to treat rare diseases. The company has established strategic partnerships with larger pharmaceutical firms, allowing it to leverage their distribution networks and gain access to broader markets. Its unique drug delivery technology provides a competitive edge by improving treatment outcomes, thus enhancing pricing power.
FDA approval of new drug candidates
Partnership announcements with larger pharmaceutical companies
Clinical trial results that exceed market expectations
Changes in regulatory policies affecting biotechnology
Regulatory changes that could impact drug approval processes
Technological disruption from emerging biopharmaceutical competitors
Increased competition from generic drug manufacturers
Potential market entry of larger pharmaceutical companies into rare disease treatments
Negative operating cash flow may limit financial flexibility
Dependence on external funding for R&D could pose liquidity risks
moderate - The biotechnology sector can be sensitive to economic cycles, as funding for R&D may fluctuate with economic conditions, impacting growth.
Interest rates affect BST.MC primarily through the cost of financing for R&D. Higher rates could increase borrowing costs, potentially limiting investment in new projects.
minimal - The company has a low debt-to-equity ratio of 0.28, indicating limited reliance on external financing.
growth - Investors looking for high-growth opportunities in the biotechnology sector will be attracted due to the company's innovative product pipeline.
high - The stock has exhibited significant volatility, reflected in a 1-year return of -43.5%.
